1. Academic Validation
  2. Inactivation of a histone methyltransferase by mutations in human cancers

Inactivation of a histone methyltransferase by mutations in human cancers

  • Cancer Res. 2003 Nov 15;63(22):7619-23.
Keun-Cheol Kim 1 Liqing Geng Shi Huang
Affiliations

Affiliation

  • 1 Program in Cancer Genetics and Epigenetics, Cancer Research Center, The Burnham Institute, La Jolla, CA 92037, USA.
PMID: 14633678
Abstract

Histone Methyltransferase (HMT)(1) class Enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain, which shares sequence homology with an independently described sequence motif, the PR domain. Intact PR or SET sequence is required for tumor suppression functions, but it remains unclear whether it is Histone Methyltransferase activity that underlies tumor suppression. We now show that tumor suppressor RIZ1 (PRDM2) methylates histone H3 on lysine 9, and this activity is reduced by mutations in the PR domain found in human cancers. Also, S-adenosylhomocysteine or methyl donor deficiency inhibits RIZ1 and Other H3 lysine 9 methylation activities. These results support the hypothesis that H3 lysine 9 methylation activities of a PR/SET domain have tumor suppression functions and may underlie carcinogenesis associated with dietary methyl donor deficiency.

Figures